Cefazolin Sodium Salt

产品说明书

Print
Chemical Structure| 27164-46-1 同义名 : 头孢唑林钠 ;Cephazolin sodium;Cefazolin sodium;SKF 41558;NSC 291561;Cefazolin (sodium salt);Ancef;cefazoline sodium
CAS号 : 27164-46-1
货号 : A188379
分子式 : C14H13N8NaO4S3
纯度 : 98%
分子量 : 476.489
MDL号 : MFCD00599428
存储条件：

Pure form Keep in dark place,Inert atmosphere,2-8°C

In solvent -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 105 mg/mL(220.36 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 100 mg/mL(209.87 mM)
动物实验配方：
生物活性
描述 Cefazolin sodium is an essential drug that is widely used in clinical therapy for certain infective diseases caused by bacteria[3]. Cefazolin sodium was given intravenously before skin incision (1 g) and at the beginning of CPB (cardiopulmonary bypass) (2 g). CPB may alter the plasma protein binding and possibly distribution of cefazolin[4]. Moreover, cefazolin has a direct anti-inflammatory effect and can attenuate surgery-induced postoperative memory and learning impairment in mice[5]. Cefazolin appears similar to oxacillin for the treatment of complicated MSSA (methicillin-susceptible Staphylococcus aureus) bacteremia but with significantly improved safety[6]. Cefazolin sodium attains high serum levels and is excreted quickly via the urine.
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02216227 Surgical Site Infection Not Applicable Recruiting September 30, 2019 United States, Florida ... 展开 >> Miami VA Healthcare System, Miami, FL Recruiting Miami, Florida, United States, 33125 Contact: Gio J Baracco Lira, MD    305-575-7000 ext 4430    Gio.Baracco@va.gov    Sub-Investigator: Gio J Baracco, MD          United States, Iowa Iowa City VA Health Care System, Iowa City, IA Recruiting Iowa City, Iowa, United States, 52246-2208 Contact: Eli N Perencevich, MD MS BS    319-338-0581 ext 3535    eli.perencevich@va.gov    Principal Investigator: Eli N. Perencevich, MD MS BS          Sub-Investigator: Heather S Reisinger, PhD          Sub-Investigator: Marin L. Schweizer-Looby, PhD BS          Sub-Investigator: Mary S. Vaughan-Sarrazin, PhD MA          United States, Maryland Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD Recruiting Baltimore, Maryland, United States, 21201 Contact: Daniel J Morgan, MD MS    (410) 706-1734    Daniel.Morgan2@va.gov    Sub-Investigator: Daniel Josiah Morgan, MD MS          United States, Massachusetts VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA Recruiting Boston, Massachusetts, United States, 02130 Contact: Kalpana Gupta, MD MPH    857-203-5086    kalpana.gupta@va.gov    Sub-Investigator: Kalpana Gupta, MD MPH          United States, Michigan VA Ann Arbor Healthcare System, Ann Arbor, MI Recruiting Ann Arbor, Michigan, United States, 48105 Contact: Suzanne F Bradley, MD    734-845-3072    Suzanne.Bradley2@va.gov    Sub-Investigator: Sarah L. Krein, PhD RN          Sub-Investigator: Suzanne F Bradley, MD          United States, Minnesota Minneapolis VA Health Care System, Minneapolis, MN Recruiting Minneapolis, Minnesota, United States, 55417 Contact: Joseph R Thurn, MD MPH    612-467-4185    seph.thurn@va.gov    Sub-Investigator: Joseph R Thurn, MD MPH          United States, Nebraska Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE Recruiting Omaha, Nebraska, United States, 68105-1873 Contact: Marvin J Bittner, MD    402-995-5219    Marvin.Bittner@va.gov    Sub-Investigator: Marvin J Bittner, MD          United States, Oregon VA Portland Health Care System, Portland, OR Recruiting Portland, Oregon, United States, 97239 Contact: Graeme N Forrest, MBBS MD    503-220-8262 ext 52118    Graeme.forrest@va.gov    Sub-Investigator: Christopher D. Pfeiffer, MD MHS          Sub-Investigator: Graeme N. Forrest, MBBS MD          United States, Texas South Texas Health Care System, San Antonio, TX Recruiting San Antonio, Texas, United States, 78229 Contact: Jose A Cadena Zuluaga, MD    210-617-5300    Jose.Cadena-Zuluaga@va.gov    Sub-Investigator: Luci Leykum, MD MBA MSc          United States, Utah VA Salt Lake City Health Care System, Salt Lake City, UT Recruiting Salt Lake City, Utah, United States, 84148 Contact: Michael A Rubin, MD PhD    (801) 582-1565 ext 1960    michael.rubin2@va.gov    Sub-Investigator: Michael Adam Rubin, MD PhD          United States, Wisconsin William S. Middleton Memorial Veterans Hospital, Madison, WI Recruiting Madison, Wisconsin, United States, 53705 Contact: Christopher J Crnich, MD PhD MS    (608) 256-1901    christopher.crnich@va.gov    Sub-Investigator: Christopher John Crnich, MD PhD MS 收起 <<
NCT02225821 Surgical Wound Infection Phase 4 Completed - Netherlands ... 展开 >> Medisch Centrum Alkmaar Alkmaar, Netherlands Flevoziekenhuis Almere, Netherlands Amstelland Ziekenhuis Amstelveen, Netherlands Academic Medical Center Amsterdam, Netherlands BovenIJ Ziekenhuis Amsterdam, Netherlands Onze Lieve Vrouwe Gasthuis Amsterdam, Netherlands Sint Lucas Andreas Ziekenhuis Amsterdam, Netherlands VU Medisch Centrum Amsterdam, Netherlands Gelre Ziekenhuizen Apeldoorn, Netherlands Rode Kruis Ziekenhuis Beverwijk, Netherlands Amphia Ziekenhuis Breda, Netherlands Reinier de Graaf Delft, Netherlands MC Haaglanden Den Haag, Netherlands Deventer Ziekenhuis Deventer, Netherlands Catharina Ziekenhuis Eindhoven, Netherlands Elkerliek Ziekenhuis Helmond, Netherlands Tergooiziekenhuizen Hilversum, Netherlands Spaarne Ziekenhuis Hoofddorp, Netherlands Westfries Gasthuis Hoorn, Netherlands Rijnland Ziekenhuis Leiderdorp, Netherlands Vlietland Ziekenhuis Schiedam, Netherlands 收起 <<
NCT02344511 Osteomyelitis Phase 3 Withdrawn April 2019 -
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.10mL

0.42mL

0.21mL

10.49mL

2.10mL

1.05mL

20.99mL

4.20mL

2.10mL
参考文献

[1]Sivakumar B, Parthasarathy K, et al. Isolation and characterisation of degradation impurities in the cefazolin sodium drug substance. Sci Pharm. 2013 Jun 4;81(4):933-50.

[2]El-Desoky HS, Ghoneim EM, Ghoneim MM. Voltammetric behavior and assay of the antibiotic drug cefazolin sodium in bulk form and pharmaceutical formulation at a mercury electrode. J Pharm Biomed Anal. 2005 Oct 4;39(5):1051-6.

[3]Chen B, Gao ZQ, Liu Y, Zheng YM, Han Y, Zhang JP, Hu CQ. Embryo and Developmental Toxicity of Cefazolin Sodium Impurities in Zebrafish. Front Pharmacol. 2017 Jun 26;8:403.

[4]Asada M, Nagata M, Mizuno T, Uchida T, Kurashima N, Takahashi H, Makita K, Arai H, Echizen H, Yasuhara M. Effects of cardiopulmonary bypass on the disposition of cefazolin in patients undergoing cardiothoracic surgery. Pharmacol Res Perspect. 2018 Nov 5;6(6):e00440.

[5]Liang P, Shan W, Zuo Z. Perioperative use of cefazolin ameliorates postoperative cognitive dysfunction but induces gut inflammation in mice. J Neuroinflammation. 2018 Aug 22;15(1):235.

[6]Li J, Echevarria KL, Hughes DW, Cadena JA, Bowling JE, Lewis JS 2nd. Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2014 Sep;58(9):5117-24.